Tag Archives: Medical Marijuana

Justin Trudeau lays down the law on marijuana during visit to Victoria

As Prime Minister Justin Trudeau discussed local issues with Mayor Lisa Helps inside Victoria City Hall Thursday afternoon, a marijuana dispensary is in clear view across the street.

During his press conference at CFB Esquimalt earlier in the day, Trudeau made his views on marijuana dispensaries clear.

“The current law remains the law. We are hoping to bring in legislation before the summer, we’re working very hard on that but I cannot stress enough, until we have a framework to control and regulate marijuana, the current law applies,” Trudeau said.

Victoria has one of the highest number of pot shops per capita in the country — there are roughly 35 operating in the city.

And rather than being shut down by police, city council has now started the process of issuing business licenses for some of them to operate.

Helps says she spoke about many things with the Prime Minister in their 30 minute meeting.

“Belleville terminal, Crystal Pool, fire hall, community benefit procurement, the opioid crisis, oil tankers,” she listed.

But marijuana never came up.

“He didn’t raise it, I didn’t raise it,” Helps said.

“I had half an hour with the Prime Minister of Canada, it’s first time since 1965 that a Prime Minister has visited, I personally and I think for our city and our region have much better things to talk about than cannabis,” she said.

Meanwhile in Langford, the city’s mayor has spoken out loudly against the one marijuana dispensary that has opened and been shut down several times in his community.

Thursday Stu Young wrote a letter to Justin Trudeau calling on him to “designate Health Canada licensed producers and pharmacies as the only distributors for cannabis.”

Adding “it would go a long way in protecting the public from illegal cannabis increasingly coming from unknown sources – and very likely from criminal elements.”

Trudeau says his goal for regulating and controlling marijuana is to take the revenue out of the pockets of criminals, and to restrict access to young people.

“It’s easier to buy a joint for a teenager than it is to buy a bottle of beer, that’s not right,” Trudeau said.

As the Prime Minister moves on to Vancouver his plan to bring in marijuana legislation by summer can’t come soon enough for many communities here on Vancouver Island.

Original article can be found here

London police raid five marijuana dispensaries

Raids were in response to community complaints, according to police

Police in London, Ont. raided five marijuana dispensaries Thursday afternoon. (Kerry McKee/CBC)

Police in London, Ont. have raided five marijuana dispensaries in response to community complaints.

Raids began at noon, according to police.

“The search warrants were in relation to possession of a controlled substance for the purpose of trafficking,” read a statement from the London Police Service.

The investigations began weeks ago, and searches at the sites are ongoing.

Marijuana dispenseries raided:

96 Wharncliffe Road South
119 Dundas Street
490 Wonderland Road South
737 Hamilton Road
1472 Dundas Street

Original article can be found here

Flying with medical marijuana? 4 things to remember

The better part of 20 years after the first Canadians were allowed to use medical marijuana, the agency that screens air passengers and their bags has explained how people should fly with their legal pot.

Medical marijuana can be carried in either carry-on or checked bags on domestic flights, the Canadian Air Transport Security Authority says, and passengers should bring documents showing their pot is legal. Screeners will ask police at the airport to look at the documents.

As recently as last December, 25-year-old Michael Korchak was denied boarding an Air Canada flight in Halifax because he was carrying medical marijuana. He was carrying all of the correct paperwork.

Korchak was prescribed marijuana to deal with pain from an injury related to military service. Air Canada has since changed its rules and offered Korchak a refund.

Cannimed, a Saskatoon-based medical marijuana producer, recommends that people not put marijuana in checked bags. Passengers could end up missing a flight if their bag is opened.
Medical marijuana users should:

Pack the pot in an easy-to-reach place in carry-on luggage, in the original packaging, with all the documents showing you possess it legally. “If they’re carrying it in their regular luggage and they do a sweep with the dogs, it’s going to get flagged,” explains Brent Zettl, Cannimed’s president. “If it gets flagged without an explanation, they have to inspect it, because they’re still looking for illegal contraband. The idea is that you have it with you so you can explain it up front, with all the paperwork.”

Call the airline in advance. “Especially in smaller airports – they’re not accustomed to seeing it very often.”

Tell the security screeners that you’re carrying marijuana.

Allow extra time for police to be called and for them to look at your paperwork.

Zettl would like to move to a system where screeners are trained to check medical marijuana documents themselves, without having to involve the police.

“You have to sit aside, you have to wait for the police to come, and it causes a delay in their travel plans. The (CATSA) staff have to be trained for this kind of thing, what to look for. They’re not trained to review those medical documents to make sure that they are legitimate. ”

Over 50,000 Canadians are authorized to use medical marijuana, Zettl said.

Original article can be found here

Teens turn to marijuana to self-medicate for stress, anxiety: report

The teen years are a high-stress, often anxiety riddled time, and research shows that young Canadians admit to turning to marijuana to cope.
Nicole* was 13 when she began using marijuana. She said at first she smoked pot due to peer pressure, but then she realized it offered her an “escape.”

“Since I was young I’ve suffered severe social anxiety which has only gotten worse,” said Nicole said in a message to Global News.
“It has and always will be the only thing that has helped with my severe anxiety and depression.”

Nicole’s story is not unusual. A new study based on cross-country focus groups found that teens are turning to marijuana to self-medicate. But experts worry they don’t always know all the risks.

“There’s this disconnect between what the scientific research shows and the thoughts and perceptions among young people,” said Amy Porath, director of research and policy at the Canadian Centre on Substance Abuse (CCSA).

The study also found that young people tend to think cannabis is not addictive, and think it’s OK to drive after smoking, Porath noted.

Adverse health effects

There is growing acceptance around using marijuana, for both recreational and medicinal purposes, as Canada moves to legalization. But smoking in youth carries greater, long-term risks.
“Young people are vulnerable as a group as well because of their ongoing brain development. Until about 20 to 25, their brains are still undergoing significant maturation and development,” said Porath.

A minimum age of 18 for access to marijuana was a key recommendation of a federal task force looking at legalization.
“The later people start using cannabis … the better,” Dr. Jürgen Rehm, director of the Institute for Mental Health Policy Research at the Centre for Addiction and Mental Health (CAMH) told Global News in December.

Cannabis is often regarded as an “innocuous” drug, a 2001 report in the British Journal of Psychiatry notes. However, evidence shows it carries dependency risks and other adverse effects, “particularly among people with pre-existing psychiatric disorders.”

“People with major mental illnesses such as schizophrenia are especially vulnerable in that cannabis generally provokes relapse and aggravates existing symptoms,” the report states.

Ethical concerns restrict research into pot’s effect on young people’s brains, said Mary Olmstead, professor of psychology and neuroscience at Queens University.

“You can’t bring people in, have them smoke pot when they’re 18 and give them a brain imaging study. We don’t do that, ethically,” Olmstead said.

In her work in the area, she typically urges young people to look for other ways to deal with their stress.

“Try yoga first.”

More guidance needed across the board

Medical marijuana users are usually adamant that it’s the best thing for what ails them. But the best way to effectively use pot for therapeutic purposes doesn’t necessarily get easier as you get older.

Medical marijuana user Jason*, 42, has a number of health issues including migraines and severe anxiety. The Torontonian has been on “pretty much every anti-depressant,” and in the past missed work at his job at a bank due to side effects.

Jason calls his cannabis use “a total game-changer.”

“I’ve tried all the meds — they don’t work. This one does.”

However, he said there’s a noted lack of guidance. Even with a prescription, without a person trained to recommend certain strains, dosage, and usage, Jason said “it really is self-medicating.”

“I would much rather have someone come to me and say, ‘this is how much you should use. This is how you use it,’” said Jason.

Still, he would rather experiment with cannabis than go back to pharmaceuticals.

Candi* started smoking marijuana at the age of 28 after a divorce.

“I had such severe depression and anxiety, it manifested as chronic migraines. I started smoking to deal with the constant pain,” said Candi.

Now 36, the rural-Manitoba resident smokes three times a day, without a prescription. Her doctor said she didn’t know enough about medical marijuana to “support prescribing it.”

For now, she relies on a trusted dealer and trial-and-error.
“Some are better than others for sure, but I smoke whatever my dealer gives me,” Candi said.

Nicole, now 34, said she’s well informed about what to consume and what to avoid, thanks to the cannabis shops increasingly popping up in Toronto — and bad experiences with the wrong strains.

“Indicas give you a huge body buzz … Sativas are meant to make you relax and focus and calm,” said Nicole.

“People need to be educated because each causes a different reaction.”

*Last names have been withheld

Original article can be found here

Oral measurement of THC intoxication level is not feasible, study concludes

A recent investigation from the University of Marseille and the Service de Pharmacocinétique Toxicocinétique provides new important data for this ongoing debate

Cannabis legalization poses considerable risks for drivers and policy makers, with multiple investigations converging on the conclusion that cannabis intoxication increases road traffic accidents and fatalities, likely due to a reduction in attention, reaction speed, and judgement of drivers (for a Lift review of the research see here).

Countries around the globe have implemented a range of policies regulating driving under the influence of cannabis. For instance, Australia prohibits driving under any detectable level of THC, whereas Switzerland has a more lax limit of 2.2 ng/ml. Across the U.S., states have imposed limits ranging from zero to 5 ng/ml.
Arguments for a zero-level tolerance posit that exact measurement of cannabis blood levels is not possible due to technological limitations and a great variability in how individuals metabolize the drug, added to the fact that even low levels of cannabinoids can impair driving significantly (especially if other substances like alcohol are also ingested).

Arguments for specific limits, on the other hand, are centered around pragmatic factors and findings that THC and other cannabis metabolites can remain detectable for nearly a week, presumably long after any psychoactive effects can still be felt. Some concerns shared by both sides revolve around the need for blood samples for adequate ruling of intoxication, due to the associated medical risks.

A recent investigation from the University of Marseille and the Service de Pharmacocinétique Toxicocinétique provides new important data for this ongoing debate. The team, led by Dr. Amélie Marsot, described in great detail the pharmacokinetic profiles of THC and its metabolites in saliva, blood plasma, and urine during the first 72 hours. Their report can be accessed for free in the Journal of Pharmacy and Pharmaceutical Sciences.

Eighteen male tobacco smokers and occasional cannabis users, aged 20 to 45 years, were recruited from the local community. Each participant underwent two treatments: a) tobacco cigarette as a control, and b) tobacco cigarette with 500 mg of cannabis (20mg of THC). To reduce differences in smoking technique, the participants followed a computerized procedure under medical supervision that explained how they should inhale the cigarette. The two treatments were separated by a 4-week washout period and randomly sorted in order to blind participants. Finally, they were asked to refrain from cannabis during the entire experiment as well as during the 28 days leading up to it.

In total, blood and oral fluids were collected 16 times each and urine was collected 6 times. The samples were tested for the presence of THC, 11-OH-THC (main psychoactive metabolic product of THC) and THC-COOH (inactive metabolite) with a minimum detection level of 1ng/ml.

The analysis yielded a wide variability in the levels of absorption, metabolism, and excretion of these metabolites. The maximum concentrations of THC ranged from 55.4 to an incredible 120000 ng/ml in saliva and 1.6 to 160 ng/ml in plasma, whereas the maximum plasma concentrations of the two metabolites varied 3 to 10 times less than this. Overall, THC salivary content was in no way indicative of THC blood content, nor were urinary samples. Other parameters such as time to maximum concentration and to last detectable concentration also varied widely across individuals.

The authors argue that oral and urinary samples can still be taken as evidence of recent use, but fail to specify what they subtend by it. In the study, half of the participants reached THC subthreshold levels in plasma in just 2 hours (maximum took 12 hours) against 18 hours in saliva (maximum took 48 hours). Urinary samples remained positive for even larger periods of time, and previous studies have shown that detection levels subsist up to 18 days after the administration of a single marijuana joint. It seems unclear what driving regulatory policy could be adopted that does not rely on blood sampling.

Featured image via Wikipedia.

Original article can be found here

Landlord pays high price for renter’s medical marijuana grow-op

‘A grow-op, whether legal or not, is still a high-risk activity,’ Insurance Bureau says

The tenant had 60 plants growing near the laundry room, landlord Darryl Spencer says. (Darryl Spencer)

Longtime landlord Darryl Spencer was left scrambling for insurance after discovering a tenant was growing dozens of medical marijuana plants inside and outside his rental house.

When the landlord told his insurance company about the perfectly legal grow-op, his coverage was cancelled, leaving him with no insurance, few rights and a big cleanup bill.

Spencer says the downstairs tenant in the Kamloops, B.C., rental property got a medical marijuana licence that allowed him to legally grow as many as 60 plants without his landlord’s permission or knowledge.

A call from a concerned neighbour prompted Spencer, who is also a retired fire inspector, to check out the home he’s rented out to different tenants for a decade.

Spencer says he’s spent thousands of dollars in order to get his rental property insurance reinstated. (CBC)

He discovered a mess of extension cords, fans and bright lights packed into a room filled with dozens of marijuana plants. The upstairs tenant, a woman with a small child, was complaining about heat radiating through the walls and electrical breakers going off.

“I was worried about the fire hazard. That was my first thought because of the extension cords, the use of electricity and that something could catch fire,” Spencer told Go Public.

Spencer’s tenant started a medical marijuana grow-op in the lower level apartment without his knowledge. (Darryl Spencer)

Under new federal rules introduced last August, landlords have little recourse if a tenant is growing licensed medical marijuana. They don’t even have the right to know it’s happening. Yet it’s landlords who are being denied insurance coverage when a tenant is growing medical pot.

Go Public also found, while the federal government implemented the rules, it wants local authorities to ensure medical grow-operations are being set up and run safely. More than 30,000 people in Canada have permits to grow cannabis for their personal medical use.

Insurance cancelled

When Spencer notified his insurance company about the tenant’s grow-op, Gore Mutual Insurance cancelled his coverage.
“They wouldn’t cover claims to do with medical marijuana or air quality contamination,” he says.

‘You can lose everything you worked so hard for your whole life.’

– Darryl Spencer, landlord

In a statement to Go Public, Gore Mutual Insurance says it “does not provide coverage for marijuana grow-operations regardless of their legality because this type of operation in a residential building presents inherent insurance risks.”

Those risks, the company says, include “a greater likelihood of water damage, mould, fire, vandalism and burglary.”

A Federal Court judge ruled last year that Canadians have a right to grow their own medical marijuana. (Darren Calabrese/Canadian Press)

Under most basic home insurance policies, marijuana-related damages or anything that companies believe is “high risk” is not covered.

That view is shared by many insurance companies, according to the Insurance Bureau of Canada.

“While regulations may allow for the legal growing of marijuana for medical purposes, it does not change the structural risk grow-ops pose to homes and condos,” Andrew McGrath, spokesman for the Insurance Bureau, tells Go Public in an email.

“The operation of a grow-op, whether legal or not, is still a high-risk activity.”

Landlord jumps through hoops

Gore Mutual Insurance told Spencer it might reinstate his coverage if he got rid of the tenant and took specific steps to ensure the house was safe to live in.

The insurance company also wanted air and soil testing, plumbing and electrical inspections, and the house checked for mould.
‘[Health Canada] basically made the decisions … in a vacuum’

– David Hutniak, Landlord B.C.

Spencer did it all, while searching for another insurance company that would cover him right away. None would.
“I went all that time with no insurance which was pretty nerve-wracking knowing there were many implications involved there. You can lose everything you worked so hard for your whole life,” he says.

The tenant did move out, but only after Spencer paid him $1,300 to leave and returned his full damage deposit despite issues with the suite.

All in, Spencer estimates he’s out more than $5,000 in costs related to the medical grow-op.

Privacy trumps landlord rights

In February 2016, a Federal Court judge gave Health Canada six months to come up with new rules that would give medical marijuana patients better access to pot, allowing more patients to grow it at home.

Spencer says he had concerns about electrical hazards in the grow-op. (Darryl Spencer)

Its response was the new Access to Cannabis for Medical Purposes Regulations, which came into effect Aug. 24, 2016.

“The new regulations do not require individuals who wish to produce a limited amount in their residence to notify or seek the consent of their landlords as such requirements would likely infringe on their right to reasonable access to cannabis for medical purposes,” Health Canada spokesman André Gagnon wrote in a statement to Go Public.

Decisions made ‘in a vacuum’

Landlord B.C., an advocacy group for landlords, says it respects the importance of marijuana therapy for those who need it. But CEO David Hutniak says the group believes property rights also are important.

“[Health Canada] basically made the decisions, from our perspective, in a vacuum,” he says.

Spencer says he was worried about safety when he saw the amount of chemicals in the tenant’s unit. (Darryl Spencer)

Hutniak says the federal government failed to provide clear direction for landlords and insurance companies when it made changes to medical marijuana rules.

Safety inspections not done

Under the new rules, Health Canada gives specific guidelines on how to safely set up medical grow-ops.

But when it comes to checking if safety rules are being followed, the federal department is leaving that to municipalities.

David Hutniak, CEO of Landlord B.C., says Health Canada should have considered the impact on property rentals and insurance when approving grow-ops. (Christer Waara/CBC)

The problem, according to the development and engineering services director for Kamloops, is federal privacy rules prevent local authorities from knowing where marijuana is being grown.

“We don’t get a list of the address, so we can’t proactively go around and do inspections,” Marvin Kwiatkowski says.

The tenant was also growing marijuana in a greenhouse on Spencer’s property. (Darryl Spencer)

There also is no system in place to proactively check if tenants are growing the allowed number of plants and following their permit.

Go Public put the issue to federal Health Minister Jane Philpott, but her office declined an interview, saying the federal government’s role is to ensure people who need medical marijuana have access.

Double the cost

Two months after his insurance was cancelled, Spencer found a company that specializes in covering medical grow-operations. The coverage cost almost twice what he used to pay and has a much higher deductible.

After Go Public contacted his original insurer, Gore Mutual, it offered to reinstate Spencer’s policy for almost the same amount he used to pay.

B.C. landlord Darryl Spencer found he had little recourse when his insurance was cancelled because a tenant was growing marijuana. (CBC)

Spencer took Gore up on the offer, and says it’s the federal government that needs to make changes.

“This has been a big mistake and I hope it gets rectified soon.”

Original article can be found here

Pinkman Goo: This Unbelievable Indica Produces Resin Dew Drops

Have you ever seen a cannabis strain that produces sap like a pine tree? One Southern Californian grower has created an indica strain unlike any other. Pinkman Goo, a strain developed by CaliCropDoc, produces a syrup-like resin that seeps out from calyxes just like sticky pine sap. Here’s why this one-of-a-kind strain is so gooey.

Pinkman Goo is one unique strain

Pinkman Goo is cannabis elevated. This indica strain produces a full droplet of resin, similar to the sticky sap found on the outside of pine trees. Such a strain is a rarity, and the stabilization of Pinkman Goo is certainly a step up in growing and cultivation.

In laboratory tests, the pinky resin from Pinkman Goo tested 4% higher in THC than resin from a non-gooey flower. The sap oozes out from between leaf margins and the bottoms of the calyx. Nighttime photosynthesis pushes plant resins up through the stem and seeps out from wherever it can.

The strain’s unique ability to produce this sap so frequently is thought to be a genetic trait, though the overall grow environment can have an impact on whether or not this process occurs.
Perhaps a bit like maple syrup, the concentrated resin from Pinkman Goo has a sweeter taste and aroma. Some suspect that the sap contains sugar crystals, that come out in the form of a sweat. The end result is a strain that looks like it has produced its own rose-colored dew droplets.

Apart from the impressive stickiness, this one-of-a-kind flower also has some seriously good looks. The leaves feature a beautiful purple-rimmed coloration and dense purple tinted buds.
This strain tests at around 18% THC, making it quite potent. The overall effects of this flower are peaceful and relaxed, and the strain features a soothing earthy aroma overall.

Who created Pinkman Goo?

Pinkman Goo was developed by grower Twompson Prater of CaliCropDoc. He inherited his gifted cultivation skills from his father and grandfather, who had purple thumbs themselves. Prater’s fifteen years of experience in medical cannabis cultivation shines through in the obvious craftsmanship behind Pinkman Goo.

CaliCropDoc wants you to know that it is possible to increase resin and coax a sappy goo from your cannabis plants. Prater offers free cannabis education through his website.

Medical and recreational growers alike can learn from Prater’s experiments, which include side by side testing, grow journals, and product reviews. Prater began CaliCropDoc to help growers sort through all of the misinformation out there and utilize safe methods that work.

For more information on expert medical cannabis cultivation or the Pinkman Goo strain, visit CaliCropDoc.org.

Original article found here

Harvard Study: Smoking Weed Improves Brain Functions

Cognitive function goes better with pot.

People are forever wandering onto KINDLAND territory and wondering out loud: What makes you people so goddamn smart?

Well, scientific findings recently published in Frontiers in Pharmacology may have cleared up that mystery once and for all. Preliminary investigations by medical researchers from McLean Hospital, Harvard Medical School, and Tufts University indicate that pot use improves cognitive performance.

Cognitive performance, no need to tell you, is “our ability to utilize the knowledge acquired by mental processes in our brains.” In other words, perform tasks that require thinking, as in to be so goddamn smart.

The behavioral scientists behind the work summarized in “Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function” tracked 24 certified medical-marijuana patients over a three-month dosing period. The patients were repeatedly measured for cognitive proficiency through challenges to the intelligence that included the Stroop Color Word Test and Trail Making Test.

Staci Gruber, PhD, director of the Marijuana Investigations for Neuroscientific Discovery (MIND) program at McLean Hospital—Harvard Medical School’s largest psychiatric affiliate—is the lead “Splendor in the Grass?” researcher. Her initial report is twofold positive. For one thing, weed treatment led to patients breezing through an array of brainteasers with enhanced speed and accuracy.

From a McLean Hospital report:

“After three months of medical marijuana treatment, patients actually performed better, in terms of their ability to perform certain cognitive tasks, specifically those mediated by the frontal cortex,” explained Gruber.

Study participants also reported improvements in their specific clinical conditions, sleep, and overall health as well as a decreased use of conventional medications, particularly opiates.

“We saw a 42 percent reduction in opioid use,” reported Gruber. “This is significant, particularly for those of us in Massachusetts and other areas of the country where the opioid epidemic is ravaging so many. This preliminary finding certainly warrants deeper and broader investigation.”

In less than a week, electorates in five states (one of them being Massachusetts) have the opportunity to vote themselves into the legal-marijuana club. If just one of these states, California for instance, opts for legal adult use, literally millions more Americans will be granted the option to use marijuana without fear of police intervention. Perhaps not everyone who picks up a joint in this newly normalized landscape will become as intelligent as the Kindland smarty’s.

But you don’t need to be a brilliant visionary to recognize that the preliminary findings from McLean Hospital’s pilot study assessing the favorable impacts of cannabis on adult human brains demand further exploration. Deeper, broader investigations into marijuana’s ability to improve our mental functioning and reduce our susceptibility to opioid dependence should be happening sooner than later.

In that regard, “Splendor in the Grass?” lead Staci Gruber appears to be every bit as invested in the public wellbeing as she is smart in her approach to unraveling and establishing best marijuana practices.
“People are going to use it,” she concludes. “It’s up to us to figure out the very best and safest ways in which they can do that.”

Original article can be found here 

Can Cannabis Chewing Gum Treat Irritable Bowel Syndrome?

A biotech firm has launched clinical trials in the Netherlands to test whether its CBD chewing gum could help treat irritable bowel syndrome.

Researchers will give a group of 40 adult patients CanChew Plus chewing gum, which contains 50 mg of hemp-derived cannabidiol per serving. Subjects will be able to take up to six servings per day under the study, which will record general relief of irritable bowel syndrome (IBS) symptoms—most often stomach cramps, bloating, and lower abdominal pain—along with any “change in stool frequency,” according to a press release.

The mint-flavored chewing gum was developed by Axim Biotechnologies, which has offices in New York and the Netherlands.

“IBS is the most common gastrointestinal disorder and affects up to 15 percent of the worldwide population,” Axim CEO Dr. George E. Anastassov said in a statement, “and It has no sustainable cure.”
The forthcoming IBS trials were developed by Axim and clinical investigators at the Wageningen University, a leading Dutch research institution and where the trials will be held.

“IBS is a very common and often painful disorder which is still difficult to manage,” Renger Witkamp, a nutrition and pharmacology professor at the school, said in a statement that accompanied the announcement. “People often experience sudden flare-ups and for many it has a negative impact on their quality of life. CBD has shown to have promising effects, but there has been a clear need for practical and effective formulations.”

While CBD is currently available in various forms, Witkamp claims that “providing it via a chewing gum results in sustained release of the compound and better bioavailability.”

Axim also makes CanChew, a controlled-release CBD chewing gum, and a combination CBD/THC gum called MedChew Rx, which is currently undergoing clinical trials for the treatment of multiple sclerosis-related pain and spasticity. Standard CanChew gum is already available in all 50 US states, the company says, as it contains only hemp-based CBD.

If the IBS trial is successful, said Axim CEO Anastassov, “we will be ready to proceed immediately with further trials on our pharmaceutical grade CanChew Rx products to treat inflammatory bowel disease (IBD), ulcerative colitis, and Crohn’s disease.”
In a legal disclosure, the company says it “does not sell or distribute any products that are in violation of the United States Controlled Substances Act”—although the DEA might disagree.

Original article can be found here